Trump Plans to Link U.S. Drug Prices to Lower Costs Abroad on Monday

---

Full Story

President Trump is set to relaunch a first-term policy Monday that ties U.S. drug prices to lower costs in other countries, aiming to reduce expenses for Americans. This approach, which seeks to align domestic prices with international benchmarks, could reshape pharmaceutical markets. The plan targets a long-standing issue in healthcare affordability.

The policy would adjust U.S. drug prices to match those in nations with lower costs. Many countries regulate drug prices, often paying less than American consumers.

MEDIA REPORTING

See how news sources on all sides are covering this story.

Left 36% | Right 24% | Center 30% | Unrated 9%

The Context

Trump’s earlier attempt at this policy faced legal and industry pushback during his first term. Drug companies argued it could stifle innovation and limit access.

The U.S. spends more per capita on prescription drugs than any other developed nation. This gap has fueled public demand for cost-control measures like price pegging.

Supporters of the plan say it could save billions for patients and insurers. Critics warn it might lead to drug shortages or reduced research funding.

The policy would likely require new regulations or executive action to implement. Its scope and timeline remain unclear pending Monday’s announcement.

Some economists argue that aligning prices could pressure foreign nations to pay more. Others doubt it will significantly lower U.S. costs without broader reforms.

Public opinion on drug pricing is mixed but leans toward favoring cost reductions. Opponents in the pharmaceutical sector may challenge the policy in court.